Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The advantages and risks of ruxolitinib for the treatment of polycythemia vera.

Expert review of hematology - 1 Oct 2020

Colafigli Gioia, Scalzulli Emilia, Pepe Sara, Di Prima Alessio, Efficace Fabio, Martelli Maurizio, Foà Robin, Breccia Massimo

Abstract excerpt

INTRODUCTION: Polycythemia vera is a myeloproliferative neoplasm characterized by an increased red blood cell mass, risk of thromboembolic events, and of transformation into secondary myelofibrosis and acute leukemia. The goal of treatment is to reduce the risk of fatal cardiovascular events reducing the hematocrit level with phlebotomies and low-dose aspirin. In high-risk patients (age >60 years or previous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Disease Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Molecular Targeted Therapy

Share to Nitriles

Share to Polycythemia Vera

Share to Pyrazoles

Share to Pyrimidines

Source

Identifiers

PMID: 32873088
DOI: 10.1080/17474086.2020.1816819

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The advantages and risks of ruxolitinib for the treatment of polycythemia vera.PMID 32873088Read ↗

Polycythemia vera: diagnosis, clinical course, and current managementSemantic proximity Read ↗

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.Semantic proximity Read ↗

How I treat polycythemia vera.Semantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Polycythemia Vera: Rapid Evidence Review.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

Polycythemia vera.Semantic proximity Read ↗

Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Molecular Characterization of Polycythemia VeraSemantic proximity Read ↗

European LeukemiaNet Clinical Signs and Symptoms as Prognostic Markers in Polycythemia Vera During RuxolitinibSemantic proximity Read ↗

Polycythaemia vera: molecular genetics, diagnostics and therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.